Biomodulators in Cancer Treatment

This publication has 23 references indexed in Scilit:

• Attempts to Optimize Active Specific Immunotherapy for Melanoma
  International Reviews of Immunology, 1991
• Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignancies
  The Lancet, 1990
• Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse
  Cancer Immunology, Immunotherapy, 1989
• p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.
  Molecular and Cellular Biology, 1989
• Protective, restorative, and therapeutic properties of recombinant human IL-1 in rodent models.
  The Journal of Immunology, 1988
• Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer Cells
  Annals of Internal Medicine, 1988
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins.
  The Journal of cell biology, 1986
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985
• Systemic bacillus Calmette-Guérin (BCG) activates natural suppressor cells.
  Proceedings of the National Academy of Sciences, 1978